

# US Patent & Trademark Office

## Patent Public Search | Text View

---

United States Patent	12390137
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Rogers; Bobby E. et al.

---

### Blood sample optimization device

---

#### Abstract

Blood sample optimization systems and methods are described that reduce or eliminate contaminants in collected blood samples, which in turn reduces or eliminates false positive readings in blood cultures or other testing of collected blood samples. A blood sample optimization system can include a blood sequestration device located between a patient needle and a sample needle. The blood sequestration device can include a sequestration chamber for sequestering an initial, potentially contaminated aliquot of blood, and may further include a sampling channel that bypasses the sequestration chamber to convey likely uncontaminated blood between the patient needle and the sample needle after the initial aliquot of blood is sequestered in the sequestration chamber.

---

**Inventors:** Rogers; Bobby E. (Park City, CA), Kang; Gino (Irvine, CA), Detloff; John (San Diego, CA)

**Applicant:** Kurin, Inc. (San Diego, CA)

**Family ID:** 1000008767842

**Assignee:** Kurin, Inc. (San Diego, CA)

**Appl. No.:** 18/898239

**Filed:** September 26, 2024

#### Prior Publication Data

Document Identifier	Publication Date
US 20250025079 A1	Jan. 23, 2025

#### Related U.S. Application Data

continuation parent-doc US 18783088 20240724 US 12138052 child-doc US 18898239  
continuation parent-doc US 18494622 20231025 US 12357209 child-doc US 18783088  
continuation parent-doc US 18113710 20230224 US 11832944 20231205 child-doc US 18494622

continuation parent-doc US 17538990 20211130 US 11963769 20240423 child-doc US 18113710  
continuation parent-doc US 16208559 20181204 US 11185266 20211130 child-doc US 17538990  
continuation parent-doc US 15994559 20180531 US 10143412 20181204 child-doc US 16208559  
continuation parent-doc US 15140448 20160427 US 10010282 20180703 child-doc US 15994559  
us-provisional-application US 62318194 20160404  
us-provisional-application US 62238636 20151007  
us-provisional-application US 62196797 20150724

---

Publication Classification

**Int. Cl.:** **A61B5/00** (20060101); **A61B5/15** (20060101); **A61B5/153** (20060101); **A61B5/154** (20060101); **A61M39/04** (20060101); **A61M39/06** (20060101); A61M39/02 (20060101)

U.S. Cl.:

CPC **A61B5/150992** (20130101); **A61B5/15003** (20130101); **A61B5/150213** (20130101); **A61B5/150221** (20130101); **A61B5/150389** (20130101); **A61B5/150473** (20130101); **A61B5/150572** (20130101); **A61B5/153** (20130101); **A61B5/154** (20130101); **A61M39/04** (20130101); **A61M39/0693** (20130101); A61M2039/0202 (20130101); A61M2039/0633 (20130101); A61M2039/068 (20130101)

Field of Classification Search

**CPC:** A61B (5/150992); A61B (5/15003); A61B (5/150213); A61B (5/150221); A61B (5/150389); A61B (5/150473); A61B (5/150572); A61B (5/153); A61B (5/154); A61M (39/04); A61M (39/0693); A61M (2039/0202); A61M (2039/0633); A61M (2039/068)

---

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
3382865	12/1967	Worrall, Jr.	N/A	N/A
3494352	12/1969	Russo	N/A	N/A
3604410	12/1970	Whitacre	N/A	N/A
3648684	12/1971	Barnwell	N/A	N/A
3741197	12/1972	Sanz	600/583	A61B 5/150267
3817240	12/1973	Ayres	600/584	A61B 5/150221
3835835	12/1973	Thompson	N/A	N/A
3848579	12/1973	Villa Real	N/A	N/A
3848581	12/1973	Cinquallbre	N/A	N/A
3859998	12/1974	Thomas	N/A	N/A
3874367	12/1974	Ayres	600/577	A61B 5/15003
3886930	12/1974	Ryan	600/584	A61B 5/150351
3945380	12/1975	Dabney	N/A	N/A
4056101	12/1976	Geissler	N/A	N/A

4057050	12/1976	Sarstedt	604/125	A61B 5/150351
4106497	12/1977	Percarpio	600/579	A61B 5/150389
4150089	12/1978	Linet	N/A	N/A
4154229	12/1978	Nugent	600/577	A61B 5/154
4193400	12/1979	Loveless	N/A	N/A
4207870	12/1979	Eldridge	604/167.03	A61B 5/150732
4257416	12/1980	Prager	N/A	N/A
4312362	12/1981	Kaufman	N/A	N/A
4349035	12/1981	Thomas	N/A	N/A
4373535	12/1982	Martell	N/A	N/A
4412548	12/1982	Hoch	600/577	A61B 5/150213
4416290	12/1982	Lutkowski	N/A	N/A
4416291	12/1982	Kaufman	N/A	N/A
4436098	12/1983	Kaufman	604/199	A61B 5/1545
4444203	12/1983	Engelman	600/576	A61B 5/150496
4673386	12/1986	Gordon	N/A	N/A
4690154	12/1986	Woodford	N/A	N/A
4813433	12/1988	Downey	N/A	N/A
4874366	12/1988	Zdeb	N/A	N/A
4904240	12/1989	Hoover	N/A	N/A
4980297	12/1989	Haynes	N/A	N/A
5045185	12/1990	Ohnaka	N/A	N/A
5097842	12/1991	Bonn	N/A	N/A
5100394	12/1991	Dudar	N/A	N/A
5135489	12/1991	Jepson	N/A	N/A
5147329	12/1991	Brannon	N/A	N/A
5200325	12/1992	Blatt	N/A	N/A
5222502	12/1992	Kurose	600/584	A61B 5/150732
5401262	12/1994	Karwoski	N/A	N/A
5417673	12/1994	Gordon	N/A	N/A
5431811	12/1994	Tusini	N/A	N/A
5432084	12/1994	Brubaker	N/A	N/A
5439450	12/1994	Haedt	N/A	N/A
5518005	12/1995	Brannon	N/A	N/A
5520193	12/1995	Suzuki	604/126	A61B 5/1545
5632906	12/1996	Ishida	N/A	N/A
5691486	12/1996	Behringer	N/A	N/A
5749857	12/1997	Cuppy	604/161	A61M 25/0606
5772608	12/1997	Dhas	N/A	N/A
5811658	12/1997	Van Driel	N/A	N/A
5865803	12/1998	Major	N/A	N/A
5873841	12/1998	Brannon	N/A	N/A
5972294	12/1998	Smith	N/A	N/A

5980830	12/1998	Savage	N/A	N/A
6013037	12/1999	Brannon	N/A	N/A
6106509	12/1999	Loubser	N/A	N/A
6126643	12/1999	Vaillancouert	N/A	N/A
6187347	12/2000	Patterson	N/A	N/A
6224561	12/2000	Swendson	N/A	N/A
6398743	12/2001	Halseth	604/164.12	A61B 5/15003
6506182	12/2002	Estabrook	N/A	N/A
6569117	12/2002	Ziv	604/246	A61M 39/02
6599474	12/2002	Evtodienko	N/A	N/A
6626884	12/2002	Dillon	N/A	N/A
6638252	12/2002	Moulton	N/A	N/A
6695004	12/2003	Raybuck	N/A	N/A
6733433	12/2003	Fell	N/A	N/A
6736783	12/2003	Blake	N/A	N/A
6843775	12/2004	Hyun	N/A	N/A
6860871	12/2004	Kuracina	N/A	N/A
6905483	12/2004	Newby	N/A	N/A
6913580	12/2004	Stone	N/A	N/A
6945948	12/2004	Bainbridge	N/A	N/A
7052603	12/2005	Schick	N/A	N/A
7055401	12/2005	Prybella	N/A	N/A
7241281	12/2006	Coelho	N/A	N/A
7306736	12/2006	Collins	N/A	N/A
7461671	12/2007	Ehwald	N/A	N/A
7479131	12/2008	Mathias	N/A	N/A
7666166	12/2009	Emmert	N/A	N/A
8070725	12/2010	Christensen	N/A	N/A
8197420	12/2011	Patton	600/573	A61B 10/0045
8349254	12/2012	Hoshino	N/A	N/A
8377040	12/2012	Burkholz	N/A	N/A
8523826	12/2012	Layton, Jr.	604/533	A61M 39/16
8535241	12/2012	Bullington	604/249	A61B 5/150251
8540663	12/2012	Davey	604/93.01	A61M 25/0029
8568371	12/2012	Siopes	251/903	A61M 39/06
8574203	12/2012	Stout	N/A	N/A
8603009	12/2012	Tan	600/573	A61B 5/150251
8827958	12/2013	Bierman	N/A	N/A
8864684	12/2013	Bullington	600/576	A61B 10/0048
9022950	12/2014	Bullington	600/576	A61B 5/153
9022951	12/2014	Bullington	600/576	A61B 5/150992
9060724	12/2014	Bullington	N/A	A61B 5/150221
9138572	12/2014	Zeytoonian	N/A	A61M 39/26
9155495	12/2014	Bullington	N/A	A61B 5/150221

9204864	12/2014	Bullington	N/A	A61B 10/0096
9820682	12/2016	Rogers	N/A	N/A
9877675	12/2017	Baid	N/A	A61B 5/150389
10010282	12/2017	Rogers	N/A	N/A
10143412	12/2017	Rogers	N/A	N/A
10265007	12/2018	Bullington	N/A	N/A
10299713	12/2018	Patton	N/A	N/A
10596315	12/2019	Bullington	N/A	N/A
10624977	12/2019	Bullington	N/A	N/A
10827964	12/2019	Rogers	N/A	N/A
10881343	12/2020	Bullington	N/A	N/A
11185266	12/2020	Rogers	N/A	N/A
11213232	12/2021	Ivosevic	N/A	N/A
11234626	12/2021	Bullington	N/A	N/A
11259727	12/2021	Bullington	N/A	N/A
11311219	12/2021	Rogers	N/A	N/A
11395612	12/2021	Bullington	N/A	N/A
11419531	12/2021	Bullington	N/A	N/A
11439332	12/2021	Bullington	N/A	N/A
11589843	12/2022	Bullington	N/A	N/A
11612340	12/2022	Bullington	N/A	N/A
11653863	12/2022	Bullington	N/A	N/A
11660030	12/2022	Bullington	N/A	N/A
11737693	12/2022	Bullington	N/A	N/A
11744494	12/2022	Rogers	N/A	N/A
11786155	12/2022	Bullington	N/A	N/A
11789017	12/2022	Bullington	N/A	N/A
2001/0044615	12/2000	Amano	N/A	N/A
2002/0004647	12/2001	Leong	604/168.01	A61B 5/15003
2003/0082074	12/2002	Jurik	N/A	N/A
2003/0105414	12/2002	Leong	600/576	A61B 5/15003
2003/0185707	12/2002	Iwaki	N/A	N/A
2003/0208151	12/2002	Kraus	N/A	N/A
2004/0054333	12/2003	Theeuwes	604/248	A61M 5/14276
2004/0073171	12/2003	Rogers	604/164.13	A61M 39/26
2004/0112808	12/2003	Takagi	N/A	N/A
2004/0116830	12/2003	Trudeau	N/A	N/A
2004/0147855	12/2003	Marsden	600/576	A61B 5/150496
2005/0004524	12/2004	Newby	604/164.08	A61B 5/150648
2005/0005635	12/2004	Le Metais	N/A	N/A
2005/0007524	12/2004	Luo	N/A	N/A
2005/0161112	12/2004	Ehwald	N/A	N/A
2005/0240161	12/2004	Crawford	604/264	A61B 5/150816
2005/0245885	12/2004	Brown	N/A	N/A
2005/0273019	12/2004	Conway	N/A	N/A

2006/0009713	12/2005	Flaherty	N/A	N/A
2007/0083162	12/2006	O'Reagan	604/167.03	A61M 39/26
2007/0088279	12/2006	Shue	604/168.01	A61M 25/0693
2007/0119508	12/2006	West	N/A	N/A
2008/0086085	12/2007	Brown	604/122	A61B 5/150389
2008/0145933	12/2007	Patton	435/379	A61B 10/0051
2008/0167577	12/2007	Weilbacher	600/576	A61B 5/1545
2008/0319346	12/2007	Crawford	600/576	A61B 5/150656
2009/0227953	12/2008	Tan	N/A	N/A
2009/0299253	12/2008	Hursey	N/A	N/A
2010/0010372	12/2009	Brown	600/573	A61B 5/15003
2010/0057004	12/2009	Christensen	604/122	A61M 25/0606
2011/0306899	12/2010	Brown	N/A	N/A
2012/0016266	12/2011	Burkholz	600/581	A61B 5/150992
2013/0116599	12/2012	Bullington	N/A	N/A
2013/0158506	12/2012	Harris	N/A	N/A
2013/0317391	12/2012	Bullington	600/578	A61B 5/15003
2014/0039348	12/2013	Bullington	N/A	N/A
2014/0073990	12/2013	Holmes	N/A	N/A
2014/0107564	12/2013	Bullington	N/A	N/A
2014/0155781	12/2013	Bullington	N/A	N/A
2014/0155782	12/2013	Bullington	N/A	N/A
2014/0163419	12/2013	Bullington	N/A	N/A
2014/0276578	12/2013	Bullington	N/A	N/A
2014/0309558	12/2013	Fletcher	N/A	N/A
2014/0323911	12/2013	Sloan	N/A	N/A
2015/0018715	12/2014	Walterspiel	N/A	N/A
2015/0246352	12/2014	Bullington	N/A	N/A
2015/0314105	12/2014	Gasparyan	N/A	N/A
2015/0342510	12/2014	Bullington	N/A	N/A
2015/0351678	12/2014	Bullington	N/A	N/A
2015/0359473	12/2014	Garrett	N/A	N/A
2016/0008579	12/2015	Burkholz	604/164.08	A61M 5/158
2016/0017488	12/2015	Kobayashi	N/A	N/A
2016/0073937	12/2015	Burkholz	N/A	N/A
2016/0161511	12/2015	Xu	N/A	N/A
2016/0174888	12/2015	Berthier	600/573	A61B 5/150503
2016/0262677	12/2015	Ebetsberger	N/A	N/A
2016/0325085	12/2015	Chelak	N/A	F16K 7/20
2016/0361006	12/2015	Bullington	N/A	N/A
2017/0020428	12/2016	Rogers	N/A	N/A
2017/0065733	12/2016	Bullington	N/A	N/A
2017/0209644	12/2016	Browka	N/A	N/A
2018/0140240	12/2017	Bullington	N/A	N/A

2018/0177445	12/2017	Rogers	N/A	N/A
2019/0159711	12/2018	Rogers	N/A	N/A
2020/0289039	12/2019	Bullington	N/A	N/A
2021/0145336	12/2020	Rogers	N/A	N/A
2021/0275068	12/2020	Miazga	N/A	N/A
2022/0151525	12/2021	Bullington	N/A	N/A
2022/0151527	12/2021	Bullington	N/A	N/A
2022/0160271	12/2021	Ivosevic	N/A	N/A
2022/0304600	12/2021	Hammer	N/A	N/A
2022/0304664	12/2021	Hammer	N/A	N/A

#### **FOREIGN PATENT DOCUMENTS**

<b>Patent No.</b>	<b>Application Date</b>	<b>Country</b>	<b>CPC</b>
2993646	12/2016	CA	N/A
101352346	12/2008	CN	N/A
205127111	12/2015	CN	N/A
7203008	12/1971	DE	N/A
2541494	12/1976	DE	N/A
29913417	12/1999	DE	N/A
10038026	12/2000	DE	N/A
10134913	12/2002	DE	N/A
10134913	12/2002	DE	N/A
10243129	12/2003	DE	N/A
0448795	12/1990	EP	N/A
0448795	12/1990	EP	N/A
1665986	12/2005	EP	N/A
2593169	12/2012	EP	N/A
3562397	12/2018	EP	N/A
3622890	12/2019	EP	N/A
S5643474	12/1980	JP	N/A
S5789869	12/1981	JP	N/A
S5825146	12/1982	JP	N/A
S5867238	12/1982	JP	N/A
H02224742	12/1989	JP	N/A
H08257018	12/1995	JP	N/A
H09504726	12/1996	JP	N/A
2001000424	12/2000	JP	N/A
2005349196	12/2004	JP	N/A
2009131273	12/2008	JP	N/A
2012016496	12/2011	JP	N/A
2013240628	12/2012	JP	N/A
5643474	12/2013	JP	N/A
5789869	12/2014	JP	N/A
5825146	12/2014	JP	N/A
5867238	12/2015	JP	N/A
2016504075	12/2015	JP	N/A
2019534792	12/2018	JP	N/A
2020000340	12/2019	JP	N/A
6643474	12/2019	JP	N/A
6734490	12/2019	JP	N/A

199216144	12/1991	WO	N/A
9605875	12/1995	WO	N/A
1996005875	12/1995	WO	N/A
2007033319	12/2006	WO	N/A
2008101025	12/2007	WO	N/A
2010062734	12/2009	WO	N/A
2011162772	12/2010	WO	N/A
2013082301	12/2012	WO	N/A
2013181352	12/2012	WO	N/A
2014058945	12/2013	WO	N/A
2017019552	12/2016	WO	N/A
2018125929	12/2017	WO	N/A
2019055487	12/2018	WO	N/A
2019232196	12/2018	WO	N/A

## OTHER PUBLICATIONS

U.S. Appl. No. 62/845,767, filed May 9, 2019, Brewer Michael. cited by applicant

International Search Report and Written Opinion dated Nov. 5, 2015, for PCT application No. PCT/US2015/035870. 6 pages. cited by applicant

Bullington, et al., Systems and Methods for Sample Collection with Reduced Hemolysis, Exhibit H in U.S. Appl. No. 62/517,681, dated Jun. 9, 2017, 131 pages. cited by applicant

Communication Under Rule 71(3) EPC dated Apr. 22, 2020 for EP application No. 17840467.9. 125 pages. cited by applicant

European Patent Application No. EP19200766.4 extended European Search Report dated Dec. 2, 2019, 11 pages. cited by applicant

European Patent Office, Extended European Search Report for European Patent Application 20197213.0-1132, dated Dec. 9, 2020, 6 pages. cited by applicant

European Patent Office; Communication pursuant to Article 94(3) EPC, dated Oct. 31, 2018; 11 pages. cited by applicant

Examination Report No. 1 dated Apr. 29, 2020, for Australian Patent Application No. 2016297849. 3 pages. cited by applicant

International Search Report and Written Opinion dated Jun. 19, 2020, for PCT application No. PCTUS2020/023617. 12 pages. cited by applicant

European Patent Office, International Search Report and Written Opinion for PCT/US16/43709, dated Oct. 19, 2016, 14 pages. cited by applicant

International Search Report/Written Opinion for PCT/US17/68569 dated Apr. 25, 2018. 9 pages. cited by applicant

Japanese Patent Office, Notice of Reasons for Rejection dated Jun. 15, 2021, Application No. JP 2019-534792, 6 pages. cited by applicant

Japanese Patent Office, Notice of Reasons for Rejection for JP Application No. JP 2020-118498 date Aug. 10, 2021. cited by applicant

Japanese Patent Office, Notice of Reasons for Rejection, Japanese patent application No. JP2018-523384, dated Jul. 23, 2019, 5 pages. cited by applicant

European Patent Office, International Search Report/Written Opinion for PCT/US17/068569 dated Apr. 25, 2018, 9 pages. cited by applicant

International Search Report and Written Opinion for PCT/US16/43709, Dated Oct. 19, 2016. 13 pages. cited by applicant

*Retractable Techs., Inc. v. Becton Dickinson & Co.*, CA No. 2:07-CV-250, Claim Construction Order (E.D. Tex., Jan. 20, 2009). 20 pages. cited by applicant

Hillyer, Christopher D., et al. "Bacterial Contamination of Blood Components: Risks, Strategies



and Regulation,” *Hematology*, 2003, pp. 575-589. cited by applicant

De Korte, Dirk, et al. “Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections.” *Vox sanguinis* 83.1 (2002): 13-16. cited by applicant

Brecher, Mark E., et al. “Bacterial contamination of blood components.” *Clinical microbiology reviews* 18.1 (2005): 195-204. cited by applicant

Van Zundert, Adrien. “New closed IV catheter system.” *Acta Anaesthesiologica Belgica* 56.3 (2005): 283-285. cited by applicant

Hall, Keri K., et al. “Updated review of blood culture contamination.” *Clinical microbiology reviews* 19.4 (2006): 788-802. cited by applicant

Page, Catherine, et al. “Blood conservation devices in critical care: a narrative review.” *Annals of intensive care* 3 [2013]: 1-6. cited by applicant

Zimmon, David S. et al. “Effect of portal venous blood flow diversion on portal pressure.” *The Journal of Clinical Investigation* 65.6 (1980): 1388-1397. cited by applicant

Patton, Richard G., et al. “Innovation for reducing blood culture contamination: initial specimen diversion technique.” *Journal of clinical microbiology* 48.12 (2010): 4501-4503. cited by applicant

Tang, Menglin, et al. “Closed blood conservation device for reducing catheter-related infections in children after cardiac surgery.” *Critical Care Nurse* 34.5 (2014): 53-60. cited by applicant

Ernst, Dennis J et al. “NCCLS simplifies the order of draw: a brief history.” *MLO: medical laboratory observer* 36.5 (2004): 1-5 pages. cited by applicant

Gottlieb, T. “Hazards of bacterial contamination of blood products.” *Anaesthesia and intensive care* 21.1 (1993): 20-23. cited by applicant

Norberg, Alonna, et al. “Contamination rates of blood cultures obtained by dedicated phlebotomy vs intravenous catheter.” *Jama* 289.6 (2003): 726-729. cited by applicant

Quilici, Nathalie, et al. “Differential quantitative blood cultures in the diagnosis of catheter-related sepsis in intensive care units.” *Clinical infectious diseases* 25.5 (1997): 1066-1070. cited by applicant

Napolitano, Marcello, et al. “Quality control of bacterial contamination of blood components: the feasibility of diversion system testing.” *Blood Transfus* 2 (2004): 231-232. cited by applicant

De Korte, Dirk, et al. “Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands.” *Transfusion* 46.3 (2006): 476-485. cited by applicant

Liumbruno, Giancarlo Maria, et al. “Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components.” *Blood Transfusion* 7.2 (2009): 86. cited by applicant

Challiner, A., et al. “Venous/arterial blood management protection system.” *Anaesthesia* 47.2 (1992): 169-169. cited by applicant

Murphy, Michael F. “Better Blood Transfusion.” *Journal of the Intensive Care Society* 4.3 (2003): 78-80. cited by applicant

Palavecino, Elizabeth L., et al. “Detecting bacterial contamination in platelet products.” *Clinical laboratory* 52.9-10 [2006]: 443-456. cited by applicant

Sheppard, Chelsea A., et al. “Bacterial contamination of platelets for transfusion: recent advances and issues.” *Laboratory Medicine* 36.12 (2005): 767-770. cited by applicant

Shulman, Gerald. “Quality of processed blood for autotransfusion.” *Journal of Extracorporeal Technology* 32.1 (2000): 11-19. cited by applicant

Weinbaum, Fredric I., et al. “Doing it right the first time: quality improvement and the contaminant blood culture.” *Journal of Clinical Microbiology* 35.3 (1997): 563-565. cited by applicant

Weinstein, Melvin P. “Blood culture contamination: persisting problems and partial progress.” *Journal of clinical microbiology* 41.6 (2003): 2275-2278. cited by applicant

Weinstein, Melvin P., et al. “The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of

bacteremia and fungemia in adults.” *Clinical Infectious Diseases* 24.4 (1997): 584-602. cited by applicant

Weinstein, Melvin P. “Current blood culture methods and systems: clinical concepts, technology, and interpretation of results.” *Clinical infectious diseases* 23.1 (1996): 40-46. cited by applicant

Closed IV, BD Saf-T-Intima. “Catheter System, Becton, Dickinson and Company, Brochure.” Retrieved from the Internet (Aug. 23, 2019). 4 pages. cited by applicant

McDonald, Carl P. “Interventions implemented to reduce the risk of transmission of bacteria by transfusion in the English National Blood Service.” *Transfusion Medicine and Hemotherapy* 38.4 (2011): 255-258. cited by applicant

Lifesciences, Edwards. “Conservation. Safety. Simplicity. Edwards Vamp and Vamp Jr. Systems.” (2002). 4 pages. cited by applicant

BD Diagnostics, “Venous Blood Collection, BD Vacutainer Passive Shielding Blood Collection Needle” literature (2005) 2 pages. cited by applicant

Barnard, Dorothy R., et al. “Fibronectin (cold insoluble globulin) in the neonate,” *The Journal of Pediatrics*, vol. 102, Issue 3, Mar. 1983, pp. 453-455. cited by applicant

Mayer, G.A. “A Method for the Reliable Determination of Clotting Time in Whole Blood,” *Canadian Medical Association Journal*, Jun. 15, 1955, vol. 72, pp. 927-929. cited by applicant

Ziegler, R., et al. “Controlled Clinical Laboratory Comparison of Two Supplemented Aerobic and Anaerobic Media Used in Automated Blood Culture Systems to Detect Bloodstream Infections,” *Journal of Clinical Microbiology*, Mar. 1998, p. 657-661. cited by applicant

Pall Medical, “Leukotrap Filtration Systems for Whole Blood Derived Platelets, Leukotrap RC PL and Leukotrap PL Systems” literature, (2005) 8 pages. cited by applicant

European Patent Application No. EP23155927.9 extended European Search Report dated Jul. 26, 2023, 8 pages. cited by applicant

Office Action (Final Rejection) dated Aug. 25, 2023 for U.S. Appl. No. 18/113,710 (pp. 1-50). cited by applicant

Notice of Allowance mailed Sep. 8, 2023; 35 page. cited by applicant

Notice of Allowance mailed Sep. 14, 2023; 90 pages. cited by applicant

Office Action (Non-Final Rejection) dated Oct. 4, 2023 for U.S. Appl. No. 17/538,990 (pp. 1-47). cited by applicant

JP Notice of Allowance mailed Jun. 20, 2023; 6 pages. cited by applicant

Examination Report dated Sep. 28, 2023, for European Patent Application No. 22181212.6. 5 pages. cited by applicant

Office Action (Notice of Section 18) dated Dec. 20, 2023 for IL App No. 309380 (pp. 1-5). cited by applicant

Notice of Allowance mailed Jan. 17, 2024; 16 pages. cited by applicant

JP Office Action mailed Feb. 27, 2024; 11 pages. cited by applicant

Office Action (Non-Final Rejection) dated Jan. 25, 2024 for IL App. 302893 (pp. 1-3). cited by applicant

Li, Yiwen, et al. “Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye Dil.” *Nature protocols* 3.11 (2008): 1703-1708. cited by applicant

Abbott Point of Care, Cartridge and Test Information, Art: 714258-010; Rev. Date: Aug. 15, 2016, 1-6 pages. cited by applicant

NCCLS. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard—Fifth dition. H3-A5, vol. 23, No. 32. Replaces H3-A4; vol. 18, No. 7. 1-52 pages. <http://demo.nextlab.ir/Organization/Documents/CLSI-Standards/CLSI-H3-A5.aspx>. cited by applicant

Perez, P., et al. “Multivariate analysis of determinants of bacterial contamination of whole-blood donations.” *Vox Sanguinis* 82.2 (2002): 55-60. cited by applicant

Sheppard, et al., Bacterial Contamination of Platelets for Transfusion: Recent Advances and Issues,

Labmedicine, vol. 36, No. 12, Dec. 2005 (“Sheppard 2005”). cited by applicant

Australian Patent Office, Examination Report No. 1 for for Australian Patent Application 2021202622, dated Mar. 18, 2022, 3 pages. cited by applicant

European Patent Office, Extended European Search Report for European Patent Application 23155927.9-1122, dated Jul. 26, 2023, pp. 1-8. cited by applicant

Notice of Allowance mailed Apr. 17, 2024; 16 pages. cited by applicant

Office Action (Non-Final Rejection) mailed Oct. 4, 2023 for U.S. Appl. No. 17/538,900 (1-47). cited by applicant

First Office Action (Non-Final Rejection) dated Aug. 3, 2023 for CN Application No. 202010300942.7. 21 pages. cited by applicant

Office Action (Non-Final Rejection) dated Feb. 21, 2023 for U.S. Appl. No. 17/893,079, pp. 1-32. cited by applicant

Office Action (Final Rejection) dated Jul. 19, 2023 for U.S. Appl. No. 17/893,079, pp. 1-21. cited by applicant

Advisory Action dated Sep. 29, 2023 for U.S. Appl. No. 17/893,079, pp. 1-24. cited by applicant

European Patent Office, Examination Report for European Patent Application 22181212.6-1122, dated Sep. 28, 2023, pp. 1-5. cited by applicant

European Patent Office, Extended European Search Report for European Patent Application 22181212.6-1122 dated Oct. 24, 2022, pp. 1-10. cited by applicant

Australian Patent Office, Australian Examination Report No. 1 for Application No. 2021120 622 dated Mar. 18, 2022, 3 pages. cited by applicant

Notice of Allowance mailed Mar. 1, 2023; 3 pages. cited by applicant

First Office Action dated Nov. 24, 2021 for IL Application No. 286030, pp. 1-3. cited by applicant

Notice of Allowance mailed Jan. 29, 2023; 87 pages. cited by applicant

Office Action (Non-Final Rejection) dated Aug. 10, 2021 for Japanese Application No. 2020-118498, pp. 1-7. cited by applicant

Office Action (Non-Final Rejection) dated Mar. 28, 2022 for Japanese Application No. 2020-118498, pp. 1-3. cited by applicant

Office Action (Non-Final Rejection) dated Sep. 1, 2022 for Japanese Application No. 2020-118498, pp. 1-4. cited by applicant

Notice of Allowance mailed Apr. 4, 2023; 6 pages. cited by applicant

Rule 71(3) Communication and Text for Grant mailed Aug. 31, 2022 for European Application No. 19200766.4-1122. 189 pages. cited by applicant

Office Action (Non-Final Rejection) mailed Jan. 21, 2022 for Israeli Application No. 267684. 3 pages. cited by applicant

Notice of Allowance mailed Feb. 14, 2023; 122 pages. cited by applicant

Office Action (Non-Final Rejection) mailed Nov. 29, 2022 for Application No. 2021-214177, pp. 1-3. cited by applicant

Notice of Allowance mailed Jun. 20, 2023; 6 pages. cited by applicant

Office Action (Non-Final Rejection) mailed Nov. 4, 2022 for U.S. Appl. No. 17/094,692, pp. 1-50. cited by applicant

Notice of Allowance mailed Apr. 20, 2023; 36 pages. cited by applicant

Office Action (Non-Final Rejection) mailed Aug. 4, 2022 for U.S. Appl. No. 16/819,033, pp. 1-35. cited by applicant

Notice of Allowance mailed Nov. 28, 2022; 9 pages. cited by applicant

Office Action (Non-Final Rejection) mailed Apr. 16, 2024 for U.S. Appl. No. 16/838,017, pp. 1-19. cited by applicant

Office Action (Non-Final Rejection) dated Sep. 17, 2024 for U.S. Appl. No. 17/893,079 (pp. 1-50). cited by applicant

Office Action (Non-Final Rejection) dated Sep. 23, 2024 for U.S. Appl. No. 17/730,118 (pp. 1-73).

cited by applicant  
Office Action (Non-Final Rejection) dated Sep. 17, 2024 for U.S. Appl. No. 18/783,088 (pp. 1-60).  
cited by applicant  
Meissner, George F. , et al., "The Standard Clotting Time, A Method Based on the Use of Whole Venous Blood in Capillary Tubes," The American Journal of Clinical Pathology, vol. 39, No. 3., pp. 321-323, Mar. 1963. cited by applicant  
Office Action (Notice of Deficiencies) dated Oct. 14, 2023 for IL App No. 309380 (pp. 1-7). cited by applicant  
Office Action (Final Rejection) dated Nov. 4, 2024 for U.S. Appl. No. 18/783,173 (pp. 1-22). cited by applicant  
Office Action (Non-Final Rejection) dated Sep. 24, 2024 for U.S. Appl. No. 18/783,173 (pp. 1-62). cited by applicant  
Office Action (Rejection Decision) dated Nov. 5, 2024 for JP Application No. 2023-076490 (pp. 1-8). cited by applicant  
Office Action (Non-Final Rejection) dated Oct. 22, 2024 for U.S. Appl. No. 18/783,173 (pp. 1-62). cited by applicant  
Office Action (Non-Final Rejection) dated Dec. 2, 2024 for U.S. Appl. No. 18/494,622 (pp. 1-70). cited by applicant  
Office Action (Advisory Action) dated Nov. 22, 2024 for U.S. Appl. No. 18/783,173 (pp. 1-3). cited by applicant  
Office Action (Non-Final Rejection) dated Feb. 11, 2025 for U.S. Appl. No. 18/783,173 (pp. 1-23). cited by applicant  
Office Action (Final Rejection) dated Dec. 31, 2024 for U.S. Appl. No. 18/783,173 (pp. 1-19). cited by applicant  
Office Action (Advisory Action) dated Mar. 12, 2025 for U.S. Appl. No. 17/893,079 (pp. 1-5). cited by applicant  
Office Action (Final Rejection) dated Feb. 12, 2025 for U.S. Appl. No. 17/730,118 (pp. 1-28). cited by applicant  
Notice of Allowance mailed Jan. 23, 2025; 121 pages. cited by applicant  
Office Action (Non-Final Rejection) dated Nov. 26, 2024 for JP Application No. 2024-121200 (pp. 1-11). cited by applicant  
Office Action (Non-Final Rejection) dated Oct. 22, 2024 for U.S. Appl. No. 18/317,558 (pp. 1-62). cited by applicant  
Notice of Allowance mailed Nov. 15, 2024, 9 pages. cited by applicant  
Office Action (Final Rejection) mailed Oct. 9, 2024 for U.S. Appl. No. 16/838,017, pp. 1-27. cited by applicant  
Office Action (Grounds) mailed Mar. 11, 2025 for Application No. 2022-572789, pp. 1-11. cited by applicant  
Office Action (Restriction Requirement) mailed Mar. 18, 2025 for U.S. Appl. No. 17/336,178, pp. 1-7. cited by applicant  
Notice of Allowance mailed Jul. 2, 2024. cited by applicant  
Office Action (Non-Final Rejection) mailed Jun. 4, 2025 for U.S. Appl. No. 17/893,079, pp. 1-34. cited by applicant

---

*Primary Examiner:* Abouelela; May A

*Attorney, Agent or Firm:* Pillsbury Winthrop Shaw Pittman LLP

---

## Background/Summary

CROSS-REFERENCE TO RELATED APPLICATIONS (1) This application is a continuation of U.S. application Ser. No. 18/783,088 filed Jul. 24, 2024, entitled “BLOOD SAMPLE OPTIMIZATION DEVICE,” which is a continuation of U.S. application Ser. No. 18/494,622 filed Oct. 25, 2023, entitled “BLOOD SAMPLE OPTIMIZATION DEVICE,” which is a continuation of U.S. application Ser. No. 18/113,710 filed Feb. 24, 2023, entitled “BLOOD SAMPLE OPTIMIZATION DEVICE,” now U.S. Pat. No. 11,832,994, which is a continuation of U.S. application Ser. No. 17/538,990 filed Nov. 11, 2021, entitled “BLOOD SAMPLE OPTIMIZATION DEVICE,” now U.S. Pat. No. 11,963,769, which is a continuation of U.S. application Ser. No. 16/208,559 filed Dec. 4, 2018, entitled “BLOOD SAMPLE OPTIMIZATION SYSTEM AND BLOOD CONTAMINANT SEQUESTRATION DEVICE AND METHOD,” now U.S. Pat. No. 11,185,266, issued Nov. 30, 2021, which is a Continuation of U.S. application Ser. No. 15/994,559, filed on May 31, 2018 and titled “BLOOD SAMPLE OPTIMIZATION SYSTEM AND BLOOD CONTAMINANT SEQUESTRATION DEVICE AND METHOD,” now U.S. Pat. No. 10,143,412, issued Dec. 4, 2018; which is a Continuation of U.S. application Ser. No. 15/140,448, filed on Apr. 27, 2016, now U.S. Pat. No. 10,010,282 issued Jul. 3, 2018, which claims the benefit of U.S. Provisional Application Ser. No. 62/196,797, filed on Jul. 24, 2015 and titled “BLOOD CULTURE IMPROVEMENT SYSTEM AND METHOD”; U.S. Provisional Application Ser. No. 62/238,636, filed on Oct. 7, 2015 and titled “BLOOD SEQUESTRATION SYSTEM FOR NON-CONTAMINATED BLOOD SAMPLING”; and U.S. Provisional Application Ser. No. 62/318,194, filed on Apr. 4, 2016 and titled “BLOOD SAMPLE OPTIMIZATION SYSTEM AND BLOOD CONTAMINANT SEQUESTRATION DEVICE AND METHOD,” the disclosures of which are incorporated by reference in their entirety.

## BACKGROUND

(1) Bacteraemia is the presence of microorganisms in the blood. Sepsis, on the other hand, is bacteraemia in the presence of clinical symptoms and signs such as fever, tachycardia, tachypnea and hypotension. Bacteraemia and sepsis are associated with a high mortality and an increased incidence and duration of hospital stay and associated costs. Many bacteraemias, sepsis, fungaemias and other pathogens actually occur within a hospital or other healthcare settings with catheters and venipunctures being a source of contamination as potential carriers of these pathogens.

(2) Blood cultures are the standard test used to detect microbial pathogens related to bacteraemia and sepsis in a patient's blood. The term blood culture refers to a single venipuncture, either from a peripheral site or central or arterial line, with the blood inoculated into one or more blood culture bottles or containers. One bottle is considered a blood culture where two or more are considered a set. Multiple sets may be obtained from multiple venipunctures and are associated with different sites on the patient.

(3) These methods allow for microbial identification and susceptibility testing to be performed, which is a critical component to managing sepsis, however the lack of rapid results and decreased sensitivity for fastidious pathogens has led to the development of improved systems and adjunctive molecular or proteomic testing.

(4) Collection of blood samples for conducting blood cultures is a critical component of modern patient care and can either positively affect the patient outcome by providing an accurate diagnosis, or can adversely affect the outcome by prolonging unnecessary antimicrobial therapy, the length of hospital stays, and increasing costs.

(5) One outcome of collection of blood cultures is contamination. Blood culture contamination can lead to a false positive culture result and/or significant increase in healthcare related costs. Sources

of blood culture contamination include improper skin antisepsis, improper collection tube disinfection, and contamination of the initial blood draw which may then skew results.

(6) Blood culture collection kits generally consist of a “butterfly” set, infusion set, or other type of venipuncture device as offered by companies like BD, Smiths, B. Braun and others, and aerobic and anaerobic blood culture bottles. Various different bottles are also available depending on the test requirements. These bottles are specifically designed to optimize recovery of both aerobic and anaerobic organisms. In conventional kits, a bottle used is known generally as a “Vacutainer,” which is a blood collection tube formed of a sterile glass or plastic tube with a closure that is evacuated to create a vacuum inside the tube to facilitate the draw of a predetermined volume of liquid such as blood.

(7) False positive blood cultures are typically a result of poor sampling techniques. They cause the use of antibiotics when not needed, increasing hospital costs and patient anxiety. Blood cultures are drawn from a needlestick into the skin, and then a Vacutainer is attached to capture a sample of blood. Contamination may occur from improper or incomplete disinfection of the skin area in and around the puncture site. It may also occur from the coring of the skin by the needle during insertion, with the cored skin cells and any associated contamination being pulled into the sample.

(8) Blood flow through a hypodermic needle is laminar, and as such, a velocity gradient can be developed over the flow tube as a pressure drop is applied to the hypodermic needle. Either forceful aspiration of blood, or using a very small hypodermic needle, can cause lysis and a release of potassium from the red blood cells, thereby rendering the blood samples abnormal.

(9) In other instances, some patients have delicate veins that can collapse under a pressure drop or vacuum, particularly as applied by a syringe's plunger that is drawn too quickly for the patient's condition. Since such condition is impossible to know beforehand, such vein collapses are a risk and very difficult to control.

(10) Various strategies have been implemented to decrease blood culture contamination rates, e.g. training staff with regard to aseptic collection technique, feedback with regard to contamination rates and implementation of blood culture collection kits. Although skin antisepsis can reduce the burden of contamination, 20% or more of skin organisms are located deep within the dermis and are unaffected by antisepsis. Changing needles before bottle inoculation is not advisable as it increases the risk to acquire needle stick injuries without decreasing contamination rates.

(11) Some conventional systems and techniques for reducing blood culture contamination include discarding the initial aliquot of blood taken from central venous catheters, venipunctures, and other vascular access systems. However, these systems require the user to mechanically manipulate an intravascular device, or require a complex series of steps that are difficult to ensure being followed.

## SUMMARY

(12) This document presents systems and methods for reducing blood culture contamination, lysing of cells, and vein collapse. In some implementations, a system and method can eliminate user variability in disinfection, and also eliminate the risk of skin cells getting into the blood culture sample. The systems and methods disclosed herein do not require a change in existing clinical processes, other than to potentially indicate when a vacutainer or other blood collection device (i.e., syringe) should be attached for drawing contaminant-free blood samples.

(13) In some implementations of the systems and methods disclosed herein the withdrawal of blood is accomplished passively by use of the patient's own blood pressure, thereby reducing the risk of vein collapse and eliminating any additional user steps over current practice. The systems and methods can be applied to accommodate short-path direct stick or butterfly venipuncture systems. They can also be used with samples drawn through a catheter.

(14) In one aspect, a blood sequestration device is presented. The blood sequestration device includes an inlet port and an outlet port. The blood sequestration device further includes a sequestration chamber connected with the inlet port, the sequestration chamber having a vent comprising an air permeable blood barrier. The blood sequestration device further includes a

sampling channel having a proximal end connected with the inlet port and a distal end connected with the outlet port.

(15) In another aspect, a blood sequestration device connected with a blood sampling pathway is described. The blood sampling pathway has a patient needle and a sample collection device. The blood sequestration device includes an inlet port connected with the patient needle, and a sequestration chamber connected with the inlet port, the sequestration chamber having a vent comprising an air permeable blood barrier. The blood sequestration device further includes a sampling channel having a proximal end connected with the inlet port, and an outlet port connected with a distal end of the sampling channel and with the sample collection device.

(16) In yet another aspect, a blood sequestration device connected with a blood sampling system is described. The blood sampling system includes a patient needle for accessing a blood sample from a patient, and a sample needle that is sealed and adapted for receiving an evacuated blood collection tube. The blood sequestration device includes an inlet port connected with the patient needle to receive the blood sample from the patient. The blood sequestration device further includes a sequestration chamber connected with the inlet port and having a vent comprising an air permeable blood barrier, the sequestration chamber for receiving and sequestering a first portion of the blood sample prior to the sample needle being unsealed by the evacuated blood collection tube. The blood sequestration device further includes a sampling channel having a proximal end connected with the inlet port, the sampling channel for conveying a subsequent portion of the blood sample once the sample needle is unsealed by the evacuated blood collection tube. The blood sequestration device further includes an outlet port connected with a distal end of the sampling channel for conveying the subsequent portion of the blood sample to the sample needle.

(17) In yet another aspect, a blood sample optimization system is disclosed and described. The blood sample optimization system includes a blood sampling system for accessing and acquiring one or more samples of a patient's blood, and a blood sequestration device for receiving and sequestering a first portion of the one or more samples of the patient's blood which might be contaminated by a venipuncture process and which could result in a false positive identification of a pathogen in the patient's blood.

(18) The blood sampling system includes a patient needle configured for a venipuncture of a patient to access a sample of blood of a patient, a blood sampling pathway connected with the patient needle for conveying the sample of blood, and a sample needle configured for receiving an evacuated blood collection container to collect and contain a subsequent portion of the sample of blood.

(19) In yet another aspect, a blood sequestration device is disclosed and described. In some implementations, the blood sequestration device can include an inlet port, an outlet port connected with the inlet port, and a sequestration chamber connected with the inlet port. The sequestration chamber can have a vent comprising an air permeable blood barrier.

(20) The blood sequestration device is connected along the blood sampling pathway between the patient needle and the sample needle, and includes an inlet port for receiving the sample of blood. The blood sequestration device further includes a sequestration chamber connected with the inlet port for receiving a first amount of the sample of blood, the sequestration chamber having a vent comprising an air permeable blood barrier for sequestering at least a first portion of the first amount of the sample of blood. The blood sequestration device may further include a sampling channel having a proximal end connected with the inlet port, the sampling channel conveying a subsequent amount of the sample of blood to the evacuated blood collection container upon the sequestration chamber sequestering at least the first portion of the first amount of the sample of blood. The blood sequestration device further includes an outlet port connected with a distal end of the sampling channel, the outlet port for outputting the subsequent amount of the sample of blood.

(21) The details of one or more embodiments are set forth in the accompanying drawings and the

description below. Other features and advantages will be apparent from the description and drawings, and from the claims.

---

## Description

### BRIEF DESCRIPTION OF THE DRAWINGS

- (1) These and other aspects will now be described in detail with reference to the following drawings.
- (2) FIG. 1 illustrates a blood sample optimization system.
- (3) FIG. 2 illustrates a blood sample optimization system in accordance with an alternative implementation.
- (4) FIG. 3 illustrates a blood sample optimization system in accordance with another alternative implementation.
- (5) FIG. 4 illustrates a blood sample optimization system in accordance with another alternative implementation.
- (6) FIG. 5 illustrates a blood sample optimization system in accordance with another alternative implementation.
- (7) FIG. 6 illustrates a blood sample optimization system in accordance with an alternative implementation.
- (8) FIG. 7 is a flowchart of a method for optimizing a quality of a blood culture.
- (9) FIGS. 8A-8E illustrate a blood sequestration system for non-contaminated blood sampling, in accordance with some implementations.
- (10) FIG. 9 illustrates a pathway splitter for use in a blood sequestrations system.
- (11) FIGS. 10A-10D illustrate a blood sequestration system for non-contaminated blood sampling, in accordance with alternative implementations.
- (12) FIGS. 11A-11E illustrate a blood sequestration system for non-contaminated blood sampling, in accordance with other alternative implementations.
- (13) FIGS. 12A-12D illustrate a blood sample optimization system including a blood sequestration device in accordance with yet other alternative implementations.
- (14) FIGS. 13A-13D illustrate a blood sample optimization system **1300** in accordance with yet another alternative implementations.
- (15) FIGS. 14A-14E illustrate yet another implementation of a blood sampling system to sequester contaminants of an initial aliquot or sample to reduce false positives in blood cultures or tests performed on a patient's blood sample.
- (16) FIGS. 15A-15G illustrate a blood sequestration device and method of using the same, in accordance with yet another implementation.
- (17) FIGS. 16A-16D illustrate a blood sequestration device in accordance with yet another implementation.
- (18) FIGS. 17A-17E illustrate a bottom member of a housing for a blood sequestration device.
- (19) FIGS. 18A-18F illustrate a top member of a housing for a blood sequestration device.
- (20) FIGS. 19A and 19B illustrate a blood sequestration device having a top member mated with a bottom member.
- (21) FIG. 20 shows a blood sample optimization system including a blood sequestration device.
- (22) FIG. 21 illustrates a non-vented blood sequestration device using a wicking material chamber.
- (23) FIGS. 22A and 22B illustrate a material makeup of a filter for sequestering blood in a sequestration chamber of a blood sequestration device.
- (24) FIGS. 23A and 23B illustrate another implementation of a blood sequestration device that uses a vacuum force from a blood collection device.
- (25) Like reference symbols in the various drawings indicate like elements.



## DETAILED DESCRIPTION

(26) This document describes blood sample optimization systems and methods for reducing or eliminating contaminants in collected blood samples, which in turn reduces or eliminates false positive readings in blood cultures or other testing of collected blood samples. In some implementations, a blood sample optimization system includes a patient needle for vascular access to a patient's bloodstream, a sample needle for providing a blood sample to a blood collection container, such as an evacuated blood collection container or tube like a Vacutainer™ or the like, or other sampling device, and a blood sequestration device located between the patient needle and the sample needle. The blood sequestration device includes a sequestration chamber for sequestering an initial, potentially contaminated aliquot of blood, and may further include a sampling channel that bypasses the sequestration chamber to convey likely uncontaminated blood between the patient needle and the sample needle after the initial aliquot of blood is sequestered in the sequestration chamber.

(27) FIG. 1 illustrates a blood sample optimization system in accordance with some implementations. The system includes a patient needle **1** to puncture the skin of a patient to access the patient's vein and blood therein. The system further includes a sample needle (i.e., a resealably closed needle for use with Vacutainers™ or the like) **5**, which may be contained within and initially sealed by a resealable boot **10**, a Luer activated valve, or another collection interface or device. The resealable boot **10** can be pushed aside or around the sample needle **5** by application of a Vacutainer™ bottle (not shown) for drawing the patient's blood. The system can further include a low volume chamber **30** that leads to the sample needle **5**, but also includes an orifice or one or more channels **45** that lead to a sequestration chamber **55** formed by a housing **50**.

(28) The sequestration chamber **55** is a chamber, channel, pathway, lock, or other structure for receiving and holding a first aliquot of the patient's blood, which may be in a predetermined or measured amount, depending on a volume of the sequestration chamber **55**. The first draw of blood typically contains or is more susceptible to containing organisms that cause bacteraemia and sepsis or other pathogens than subsequent blood draws. The sequestration chamber **55** can be a vessel encased in a solid housing, formed in or defined by the housing itself, or can be implemented as tubing or a lumen. The sequestration chamber **55**, regardless how formed and implemented, may have a predetermined volume. In some implementations, the predetermined volume may be based on a volume of the patient needle, i.e. ranging from less than the volume of the patient needle to any volume up to or greater than 20 times or more of the volume of the patient needle. The predetermined volume of the sequestration chamber **55** may also be established to economize or minimize an amount of blood to be sequestered and disposed of.

(29) The sequestration chamber **55** can be formed, contained or housed in a chamber housing **50**, and can be made of plastic, rubber, steel, aluminum or other suitable material. For example, the sequestration chamber **55** could be formed of flexible tubing or other elastomeric materials. The sequestration chamber **55** further includes an air permeable blood barrier **20** that allows air to exit the sequestration chamber **55**. As used herein the term “air permeable blood barrier” means an air permeable but substantially blood impermeable substance, material, or structure. Examples may include hydrophobic membranes and coatings, a hydrophilic membrane or coating combined with a hydrophobic membrane or coating, mesh, a filter, a mechanical valve, antimicrobial material, or any other means of allowing air to be displaced from the sequestration chamber **55** as it is filled with blood. In various exemplary embodiments, an air permeable blood barrier may be formed by one or more materials that allow air to pass through until contacted by a liquid, such material then becomes completely or partially sealed to prevent or inhibit the passage of air and/or liquid. In other words, prior to contact with liquid, the material forms a barrier that is air permeable. After contact with a liquid, the material substantially or completely prevents the further passage of air and/or liquid.

(30) The orifice or channel **45** can be any desired length, cross-sectional shape or size, and/or can

be formed to depart from the low volume chamber **30** at any desired angle or orientation. The orifice or channel **45** may also include a one-way flap or valve **60** that maintains an initial aliquot of blood sample within the sequestration chamber **55**. In some specific implementations, the orifice or channel **45** can include a “duck bill” or flapper valve **60**, or the like, for one-way flow of blood from low volume chamber **30** to the sequestration chamber **55**. The air permeable blood barrier **20** can also be constructed of a material that allows air to exit but then seals upon contact with blood, thereby not allowing external air to enter sequestration chamber **55**. This sealing would eliminate the need for a valve.

(31) Valve **60** can be any type of valve or closing mechanism. Chamber **30** is designed to hold virtually no residual blood, and can be designed to be adapted to hold or allow pass-through of a particular volume or rate of blood into sequestration chamber **55**. Likewise, sequestration chamber **55** may also include any type of coating, such as an anti-microbial coating, or a coating that aids identification and/or diagnosis of components of the first, sequestered blood draw.

(32) Housing **50** and **40** can be formed of any suitable material, including plastic, such as acrylonitrile butadiene styrene (ABS) or other thermoplastic or polymeric material, rubber, steel, or aluminum. The air permeable blood barrier **20** can include a color-providing substance, or other signaling mechanism, that is activated upon contact with blood from the initial blood draw, or when air displacement is stopped, or any combination of events with blood in the sequestration chamber **55**. The air permeable barrier may also include an outer layer such as a hydrophobic membrane or cover that inhibits or prevents the inadvertent or premature sealing of the filter by an external fluid source, splash etc. Sequestration chamber **55** can also be translucent or clear to enable a user to visually confirm the chamber is filled.

(33) FIG. 2 illustrates a blood sample optimization system in accordance with some alternative implementations. In the implementation shown in FIG. 2, a sequestration chamber **55**, or waste chamber, surrounds the patient needle **1**, with an open-ended cuff or housing connected with the waste chamber and encircling the sample needle housing base and housing. The patient needle **1** and sample needle **5** are connected together by a boot **56**, which forms a continuous blood draw channel therethrough. The boot **56** includes a single orifice or channel leading from the blood draw channel into sequestration chamber **55**. The device can include more than one single orifice or channel, in other implementations. Each orifice or channel can include a one-way valve, and can be sized and adapted for predetermined amount of blood flow.

(34) The sequestration chamber **55** includes an air permeable blood barrier. The filter can further include a sensor or indicator to sense and/or indicate, respectively, when a predetermined volume of blood has been collected in the sequestration chamber **55**. That indication will alert a user to attach an evacuated blood collection tube or bottle, such as a Vacutainer™ to the sample needle **5**. The housing for the sequestration chamber **55** can be any size or shape, and can include any type of material to define an interior space or volume therein. The interior space is initially filled only with air, but can also be coated with an agent or substance, such as a decontaminate, solidifying agent, or the like. Once evacuated blood collection tube is attached to the sample needle **5**, blood will flow automatically into the patient needle **1**, through the blood draw channel and sample needle **5**, and into the bottle. The sample needle **5** is covered by a resealable boot, coating or membrane that seals the sample needle when a blood collection bottle is not attached thereon or thereto.

(35) FIG. 3 illustrates a blood sample optimization system in accordance with some alternative implementations. In the implementation shown, a sample needle **5** is surrounded by a resalable boot or membrane, and is further connected with a patient needle **1**. A blood flow channel is formed through the sample needle and the patient needle. The connection between the sample needle and patient needle includes a “T” or “Y” connector **102**, which includes a channel, port or aperture leading out from the main blood flow channel to a sequestration chamber **104**.

(36) The T or Y connector **102** may include a flap or one-way valve, and have an opening that is sized and adapted for a predetermined rate of flow of blood. The sequestration chamber **104** can be

formed from tubing, or be formed by a solid housing, and is initially filled with air. The sequestration chamber **104** will receive blood that flows out of a patient automatically, i.e. under pressure from the patient's own blood pressure. The sequestration chamber **104** includes an air permeable blood barrier **106**, preferably at the distal end of tubing that forms the sequestration chamber **104**, and which is connected at the proximal end to the T or Y connector **102**. The T or Y connector **102** can branch off at any desired angle for most efficient blood flow, and can be formed so as to minimize an interface between the aperture and channel and the main blood flow channel, so as to minimize or eliminate mixing of the initial aliquot of blood with main blood draw samples. (37) In some alternative implementations, the sample needle may be affixed to a tubing of any length, as shown in FIG. 4, connecting at its opposite end to the T or Y connector **102**. The sequestration chamber **104** can be any shape or volume so long as it will contain a predetermined amount of blood sample in the initial aliquot. The T or Y connector **102** may also include an opening or channel that is parallel to the main blood flow channel. The air permeable blood barrier may further include an indicator **107** or other mechanism to indicate when a predetermined amount of blood has been collected in the sequestration chamber, or when air being expelled reaches a certain threshold, i.e. to zero. The tubing can also include a clip **109** that can be used to pinch off and prevent fluid flow therethrough.

(38) Once the air permeable blood barrier and primary chamber are sealed the initial aliquot of blood is trapped in the sequestration chamber **104**, an evacuated blood collection tube, such as a Vacutainer™ bottle may be attached to the sample needle **5** to obtain the sample. The blood collection tube can be removed, and the sample needle **5** will be rescaled. Any number of follow-on blood collection tubes can then be attached for further blood draws or samples. Upon completion of all blood draws, the system can be discarded, with the initial aliquot of blood remaining trapped in the sequestration chamber **104**.

(39) FIG. 5 illustrates a blood sample optimization system in accordance with some alternative implementations. In the implementation shown, a sample needle **5** is connected with a patient needle by tubing. A “T” or “Y” connector **120** is added along the tubing at any desired location, and includes an aperture, port or channel leading to a sequestration chamber **204**, substantially as described above.

(40) FIG. 6 illustrates a blood sample optimization system in accordance with some alternative implementations, in which a sequestration chamber **304**, formed as a primary collection channel, receives an initial aliquot of blood, and is provided adjacent to the blood sampling channel. The sequestration chamber **304** can encircle the blood sampling channel, the patient needle **1**, and/or the sample needle **5**. The primary collection channel can include a Tor Y connector **120**, or other type of aperture or channel. The sequestration chamber **304** includes an air permeable blood barrier, which can also include an indicator of being contacted by a fluid such as blood, as described above.

(41) In some implementations, either the patient needle **1** or the sample needle **5**, or both, can be replaced by a Luer lock male or female connector. However, in various implementations, the connector at a sample needle end of the blood sample optimization system is initially sealed to permit the diversion of the initial aliquot of blood to the sequestration chamber, which is pressured at ambient air pressure and includes the air outlet of the air permeable blood barrier. In this way, the system passively and automatically uses a patient's own blood pressure to overcome the ambient air pressure of the sequestration chamber to push out air through the air permeable blood barrier and displace air in the sequestration chamber with blood.

(42) FIG. 7 is a flowchart of an exemplary method for optimizing the quality of a blood culture. At **702**, a clinician places a needle into a patient's vein. At **704**, blood then flows into a sequestration chamber, pushing the air in the sequestration chamber out of the sequestration chamber through an air permeable blood barrier. In some implementations, the volume of the sequestration chamber is less than 0.1 to more than 5 cubic centimeters (cc's), or more. The sequestration chamber is sized and adapted to collect a first portion of a blood sample, which is more prone to contamination than

secondary and other subsequent portion of the blood sample or subsequent draws. Since the sequestration chamber has an air-permeable blood barrier through which air can be displaced by blood pushed from the patient's vein, such blood will naturally and automatically flow into the sequestration chamber before it is drawn into or otherwise enters into a Vacutainer or other bottle for receiving and storing a blood sample.

(43) When the sequestration chamber fills, the blood will gather at or otherwise make contact with the air permeable blood barrier, which will inhibit or prevent blood from passing therethrough. At **706**, when the blood comes into contact with the entire internal surface area of the air permeable blood barrier, the air permeable blood barrier is then closed and air no longer flows out or in. At **708**, the clinician may be provided an indicator or can see the full chamber, to indicate the evacuated blood collection tube, such as a Vacutainer™ can be attached. The indicator can include visibility into the primary chamber to see whether it is full, the blood barrier changing color, for example, or other indicator. The fill time of the sequestration chamber may be substantially instantaneous, so such indicator, if present, may be only that the sequestration chamber is filled.

(44) Prior to an evacuated blood collection tube being attached, communication between the needle, sampling channel, and the sequestration chamber is restricted by the scaling of the sequestration chamber blood barrier thereby not permitting air to reenter the system through the sequestration. Sealing the communication path could also be accomplished with a mechanical twist or other movement, a small orifice or tortuous pathway, eliminating the need for a separate valve or mechanical movement or operation by the clinician. At **710**, once the evacuated blood collection tube is removed, the self-scaling membrane closes the sample needle, and at **712**, additional subsequent evacuated blood collection tubes may be attached. Once samples have been taken, at **714** the device is removed from the patient and discarded.

(45) FIGS. **8A-8E** illustrate an exemplary blood sample optimization system **800** for non-contaminated blood sampling, in accordance with some implementations. The blood sample optimization system **800** includes an inlet port **802** that can be connected to tubing, a patient needle (or both), or other vascular or venous access device, and a pathway splitter **804** having a first outlet to a sequestration chamber tubing **806** and a second outlet to sample collection tubing **808**. One or both of the sequestration chamber tubing **806** and the sample collection tubing **808** can be formed of tubing. In some implementations, the sequestration chamber tubing **806** is sized so as to contain a particular volume of initial blood sample. The sample collection tubing **808** will receive a blood sample once the sequestration chamber tubing **806** is filled. The sample collection tubing **808** can be connected to a Vacutainer™ base or housing **810**, or other blood sample collection device.

(46) The blood sequestration system **800** further includes a blood sequestration device **812** which, as shown in more detail in FIGS. **8B-8D**, includes a housing **818** that includes a sampling channel **820** defining a pathway for the non-contaminated sample collection tubing **808** or connected at either end to the non-contaminated sample collection tubing **808**. The sampling channel **820** can be curved through the housing **818** so as to better affix and stabilize the housing **818** at a location along the non-contaminated sample collection tubing **808**.

(47) The blood sequestration device **812** further includes a sequestration chamber **822** connected with the sequestration chamber tubing **806** or other chamber. The sequestration chamber **822** terminates at an air permeable blood barrier **824**. The air permeable blood barrier **824** can also include a coloring agent that turns a different color upon full contact with blood, as an indicator that the regular collection of blood samples (i.e. the non-contaminated blood samples) can be initiated. Other indicators may be used, such as a small light, a sound generation mechanism, or the like. In some implementations, the air permeable blood barrier is positioned at a right angle from the direction of sequestration chamber **822**, but can be positioned at any distance or orientation in order to conserve space and materials used for the housing **818**. The housing **818** and its contents can be formed of any rigid or semi-rigid material or set of materials.

(48) FIG. **9** illustrates a pathway splitter **900** for use in a blood sequestrations system, such as those

shown in FIGS. 8A-8E, for example. The pathway splitter **900** includes an inlet port **902**, a main line outlet port **904**, and a sequestration channel outlet port **906**. The inlet port **902** can be connected to main tubing that is in turn connected to a patient needle system, or directly to a patient needle. The main line outlet port **904** can be connected to main line tubing to a blood sampling system, such as a vacutainer base or housing, or directly to such blood sampling system. The sequestration channel outlet port **906** can be connected to sequestration tubing for receiving and sequestering a first sample of blood, up to a measured amount or predetermined threshold. Alternatively, the sequestration channel outlet port **906** can be connected to a sequestration chamber. The sequestration channel outlet port **906** is preferably 20-70 degrees angled from the main line outlet port **904**, which in turn is preferably in-line with the inlet port **902**. Once the predetermined amount of initial blood sample is sequestered in the sequestration tubing or chamber, in accordance with mechanisms and techniques described herein, follow-on blood samples will flow into the inlet port **902** and directly out the main line outlet port **904**, without impedance.

(49) FIGS. **10A-10D** illustrate a blood sequestration device **1000** in accordance with alternative implementations. The blood sequestration device **1000** includes an inlet port **1002**, a main outlet port **1004**, and a sequestration channel port **1006**. The inlet port **1002** can be connected to a patient needle or related tubing. The main outlet port **1004** can be connected to a blood sample collection device such as a Vacutainer, associated tubing, or a Luer activated valve, or the like. The sequestration channel port **1006** splits off from the main outlet port **1004** to a sequestration chamber **1008**. In some implementations, the sequestration chamber **1008** is formed as a helical channel within a housing or other container **1001**.

(50) The sequestration chamber **1008** is connected at the distal end to an air permeable blood barrier **1010**, substantially as described above. Air in the sequestration chamber **1008** is displaced through the air permeable blood barrier **1010** by an initial aliquot of blood that is guided into the sequestration channel port **1006**. Once the sequestration chamber **1008** is filled, further blood draws through the main outlet port **1004** can be accomplished, where these samples will be non-contaminated.

(51) FIGS. **11A-11E** illustrate a blood sequestration device **1100** in accordance with other alternative implementations. The blood sequestration device **1100** includes an inlet port **1102**, similar to the inlet ports described above, a main outlet port **1104**, and a sequestration channel port **1106** that splits off from the main outlet port **1104** and inlet port **1102**. The sequestration channel port is connected to a sequestration chamber **1108**. In the implementation shown in FIGS. **11A-11E**, the blood sequestration device includes a base member **1101** having a channel therein, which functions as the sequestration chamber **1108**. The channel can be formed as a tortuous path through the base member **1101**, which is in turn shaped and formed to rest on a limb of a patient.

(52) A portion of the sequestration chamber **1108** can protrude from the base member or near a top surface of the base member, just before exiting to an air permeable blood barrier **1110**, to serve as a blood sequestration indicator **1109**. The indicator **1109** can be formed of a clear material, or a material that changes color when in contact with blood.

(53) In some implementations, the blood sequestration device **1100** can include a blood sampling device **1120** such as a normally closed needle, Vacutainer™ shield or other collection device. The blood sampling device **1120** can be manufactured and sold with the blood sequestration device **1100** for efficiency and convenience, so that a first aliquot of blood that may be contaminated by a patient needle insertion process can be sequestered. Thereafter, the blood sampling device **1120** can draw non-contaminated blood samples to reduce the risk of false positive testing and ensure a non-contaminated sample.

(54) FIGS. **12A-12D** illustrate a blood sample optimization system **1200** in accordance with yet other alternative implementations. The system **1200** includes a blood sequestration device **1202** for attaching to a blood sampling device **1204**, such as a Vacutainer™ or other collection and sampling

device. The blood sequestration device **1202** is configured and arranged to receive, prior to a Vacutainer™ container or vial being attached to a collection needle of the blood sampling device **1204**, a first aliquot or amount of blood, and sequester that first aliquot or amount in a sequestration channel of the blood sequestration device **1202**.

(55) In some implementations, the blood sequestration device **1202** can include an inlet port **1212**, a main outlet port, and a sequestration channel port. The inlet port **1212** can be connected to a patient needle or related tubing. The main outlet port **1214** can be connected to a normally closed needle or device to enable connection with an evacuated blood collection container or other collection device such as a Vacutainer™, associated tubing, luer connectors, syringe, a Luer activated valve, or the like. The sequestration channel port splits off from the main outlet port to a sequestration chamber **1218**.

(56) In some implementations, the sequestration chamber **1218** is formed as a channel within the body of a sequestration device **1202**. The sequestration chamber **1218** can be a winding channel, such as a U-shaped channel, an S-shaped channel, a helical channel, or any other winding channel. The sequestration device **1202** can include a housing or other containing body, and one or more channels formed therein. As shown in FIGS. **12A** and **12B**, the sequestration device **1202** includes a main body **1206** and a cap **1208**. The main body **1206** is formed with one or more cavities or channels, which are further formed with one or more arms **1210** that extend from the cap **1208**, and which abut the cavities or channels in the main body **1206** to form the primary collection port and main outlet port.

(57) FIGS. **13A-13D** illustrate a blood sample optimization system **1300** in accordance with yet other alternative implementations. The system **1300** includes a blood sequestration device **1302** for attaching to a blood sampling device **1304**, such as a Vacutainer or other bodily fluid collection and sampling device. The blood sequestration device **1302** is configured and arranged to receive, prior to a Vacutainer container or vial being attached to a collection needle of the blood sampling device **1304**, a first aliquot or amount of blood, and to sequester that first aliquot or amount of blood or other bodily fluid in a sequestration channel of the blood sequestration device **1302**.

(58) The blood sequestration device **1302** includes a housing **1301** having an inlet port **1314**, a main outlet port **1312**, and a sequestration channel port **1316**. The inlet port **1314** can be connected to a patient needle or associated tubing. The main outlet port **1312** can be connected to a normally closed needle or device to enable connection with an evacuated blood collection container or other collection device such as a Vacutainer™, associated tubing, luer connectors, syringe, a Luer activated valve, or the like. The sequestration channel port **1316** splits off from the main inlet port **1314** to a sequestration chamber **1318**.

(59) In the implementation shown in FIGS. **13A-D**, the sequestration chamber **1318** is formed as a cavity or chamber within housing **1301** or formed by walls that define housing **1301**. The sequestration chamber **1318** can be a winding channel, such as a U-shaped channel, an S-shaped channel, a helical channel, or any other winding channel, that is defined by the cooperation and connection of housing **1301** with cap **1307** which cap **1307** can include a protrusion **1305** that provides one or more walls or directors for the winding channel in the sequestration chamber **1318**. The protrusion **1305** from the cap **1307** can be straight or curved, and may have various channels, apertures or grooves embedded therein, and can extend from the cap **1307** any angle or orientation. When the cap **1307** is connected with the housing **1301** to complete the formation of the sequestration chamber **1318**, the protrusion **1305** forms at least part of the winding channel to sequester a first aliquot or amount of blood or other bodily fluid in a sequestration channel formed in the sequestration chamber **1318** and by the winding channel.

(60) The sequestration chamber **1318** includes an air permeable blood barrier **1310**, substantially as described above. Air in the sequestration chamber **1318** is displaced through the air permeable blood barrier **1310** by an initial aliquot of blood that is provided into the sequestration chamber **1318** by the blood pressure of the patient. Once the sequestration chamber **1318** is filled and the air

in the sequestration chamber **1318** displaced, the blood pressure of the patient will be insufficient to drive or provide further blood into the blood sequestration device **1302**, and in particular the outlet port **1312**, until a force such as a vacuum or other pressure, such as provided by the blood sample collection device like Vacutainer is provided to draw out a next aliquot or amount of blood or bodily fluid. Further blood draws through the main outlet port **1312** can be accomplished, where these samples will be non-contaminated since any contaminants would be sequestered in the sequestration chamber **1318** with the first aliquot of blood.

(61) FIGS. **14A-14E** illustrate yet another implementation of a blood sampling system **1400** to sequester contaminants of an initial aliquot or sample to reduce false positives in blood cultures or tests performed on a patient's blood sample. The blood sampling system **1400** includes a blood sequestration device **1401** that can be connected between a blood sample collection device **1403** and a patient needle (not shown). The blood sample collection device **1403** can be a Vacutainer or the like. The blood sequestration device **1401** includes an inlet port **1402** that can be connected with a patient needle that is inserted into a patient's vascular system for access to and withdrawing of a blood sample. The inlet port **1402** may also be connected with tubing or other conduit that is in turn connected with the patient needle.

(62) The inlet port **1402** defines an opening into the blood sequestration device **1401**, which opening can be the same cross sectional dimensions as tubing or other conduit connected with the patient needle or the patient needle itself. For instance, the opening can be circular with a diameter of approximately 0.045 inches, but can have a diameter of between 0.01 inches or less to 0.2 inches or more. The blood sequestration device **1401** further includes an outlet port **1404**, which defines an opening out of the blood sequestration device **1401** and to the blood sample collection device **1403**. The outlet port **1404** may also be connected with tubing or other conduit that is in turn connected with the blood sequestration device **1403**. The outlet port **1404** can further include a connector device such as a threaded cap, a Luer connector (male or female), a non threaded interference or glue joint fitting for attachment of various devices including but not limited to tubing, or the like.

(63) The blood sequestration device **1401** further includes a sampling channel **1406** between the inlet port **1402** and the outlet port **1404**, and which functions as a blood sample pathway once a first aliquot of blood has been sequestered. The sampling channel **1406** can be any sized, shaped or configured channel, or conduit. In some implementations, the sampling channel **1406** has a substantially similar cross sectional area as the opening of the inlet port **1402**. In other implementations, the sampling channel **1406** can gradually widen from the inlet port **1402** to the outlet port **1404**.

(64) The blood sequestration device **1401** further includes a sequestration chamber **1408** that is connected to and split off or diverted from the sampling channel **1406** at any point between the inlet port **1402** and the outlet port **1404**, but preferably from a proximal end of the sampling channel **1406** near the inlet port **1402**. The sequestration chamber **1408** is at first maintained at atmospheric pressure, and includes an air outlet **1412** at or near a distal end of the sequestration chamber **1408** opposite the diversion point from the sampling channel **1406**. The air outlet **1412** includes an air permeable blood barrier **1412**. As shown in FIG. **14B**, the air permeable blood barrier **1412** can be overlaid with a protective cover **1416**. The protective cover **1416** can be sized and configured to inhibit a user from touching the air permeable blood barrier **1412** with their finger or other external implement, while still allowing air to exit the air permeable blood barrier **1412** as the air is displaced from the sequestration chamber **1408** by blood being forced into the sequestration chamber **1408** by a patient's own blood pressure. In addition the protective cover **1416** can be constructed to inhibit or prevent accidental exposure of the air permeable blood barrier to environmental fluids or splashes. This can be accomplished in a variety of mechanical ways including but not limited to the addition of a hydrophobic membrane to the protective cover.

(65) As shown in FIGS. **14C** and **14D**, the sampling channel **1406** can be cylindrical or frusto-

conical in shape, going from a smaller diameter to a larger diameter, to minimize a potential to lyse red blood cells. Likewise, the sampling channel **1406** is formed with a minimal amount of or no sharp turns or edges, which can also lyse red blood cells. The sampling channel **1406** splits off to the sequestration chamber **1408** near the inlet port **1402** via a diversion pathway **1409**. The diversion pathway **1409** can have any cross-sectional shape or size, but is preferably similar to the cross-sectional shape of at least part of the inlet port **1402**.

(66) In some implementations, the sampling channel **1406** and the sequestration chamber **1408** are formed by grooves, channels, locks or other pathways formed in housing **1414**. The housing **1414** can be made of plastic, metal or other rigid or semi-rigid material. The housing **1414** can have a bottom member that sealably mates with a top member. One or both of the bottom member and the top member can include the sampling channel **1406** and the sequestration chamber **1408**, as well as the diversion pathway **1409**, the inlet port **1402**, and the outlet port **1404**. In some other implementations, one or more of the diversion pathway **1409**, the inlet port **1402**, and/or the outlet port **1404** can be at least partially formed by a cap member that is connected to either end of the housing **1414**. In some implementations, the top member and the bottom member, as well as the cap member(s), can be coupled together by laser welding, heat sealing, gluing, snapping, screwing, bolting, or the like. In other implementations, some or all of the interior surface of the diversion pathway **1409** and/or sequestration chamber **1408** can be coated or loaded with an agent or substance, such as a decontaminate, solidifying agent, or the like. For instance, a solidifying agent can be provided at the diversion pathway **1409** such that when the sequestration chamber **1408** is filled and the initial aliquot of blood backs up to the diversion pathway **1409**, that last amount of sequestered blood could solidify, creating a barrier between the sequestration chamber **1408** and the sampling channel **1406**.

(67) FIGS. **15A-15G** illustrate a blood sequestration device **1500**. The blood sequestration device **1500** can be connected to a normally closed needle or device to enable connection with an evacuated blood collection container or other collection device such as a Vacutainer™, associated tubing, luer connectors, syringe, a Luer activated valve, or the like.

(68) The blood sequestration device **1500** includes an inlet port **1502** that can be connected with a patient needle that is inserted into a patient's vascular system for access to and withdrawing of a blood sample. The inlet port **1502** may also be connected with tubing or other conduit that is in turn connected with the patient needle. The inlet port **1502** defines an opening into the blood sequestration device **1500**, which opening may be the same cross sectional dimensions as tubing or other conduit connected with the patient needle or the patient needle itself. For instance, the opening can be circular with a diameter of approximately 0.045 inches, but can have a diameter of between 0.01 inches or less to 0.2 inches or more.

(69) The inlet port **1502** can also include a sealing or fluid-tight connector or connection, such as threading or Luer fitting, or the like. In some implementations, tubing or other conduit associated with the patient needle can be integral with the inlet port **1502**, such as by co-molding, gluing, laser weld, or thermally bonding the parts together. In this manner, the blood sequestration device **1500** can be fabricated and sold with the patient needle as a single unit, eliminating the need for connecting the patient needle to the blood sequestration device **1500** at the time of blood draw or sampling.

(70) The blood sequestration device **1500** further includes an outlet port **1504**, which defines an opening out of the blood sequestration device **1500** and to the blood sample collection device. The outlet port **1504** may also be connected with tubing or other conduit that is in turn connected with the blood sequestration device, and may also include a sealing or fluid-tight connector or connection, such as threading or Luer fitting, or the like. Accordingly, as discussed above, the blood sequestration device **1500** can be fabricated and sold with the patient needle and/or tubing and the blood sample collection device as a single unit, eliminating the need for connecting the patient needle and the blood sample collection device to the blood sequestration device **1500** at the



time of blood draw or sampling.

(71) The blood sequestration device **1500** further includes a sampling channel **1506** between the inlet port **1502** and the outlet port **1504**, and which functions as a blood sample pathway once a first aliquot of blood has been sequestered. The sampling channel **1506** can be any sized, shaped or configured channel or conduit. In some implementations, the sampling channel **1506** has a substantially similar cross sectional area as the opening of the inlet port **1502**. In other implementations, the sampling channel **1506** can gradually widen from the inlet port **1502** to the outlet port **1504**.

(72) The blood sequestration device **1500** further includes a sequestration chamber **1508** that is connected to and split off or diverted from the sampling channel **1506** at any point between the inlet port **1502** and the outlet port **1504**, but preferably from a proximal end of the sampling channel **1506** near the inlet port **1502**. In some implementations, the diversion includes a Y-shaped junction. The sequestration chamber **1508** is preferably maintained at atmospheric pressure, and includes a vent **1510** at or near a distal end of the sequestration chamber **1508**. The vent **1510** includes an air permeable blood barrier **1512**. FIG. 15C illustrates the blood sequestration device **1500** with the sequestration chamber **1508** filled with a first aliquot or sample of blood from the patient.

(73) The air permeable blood barrier **1512** can be covered with a protective cover **1516**. The protective cover **1516** can be sized and configured to inhibit a user from touching the air permeable blood barrier **1512** with their finger or other external implement, while still allowing air to exit the air permeable blood barrier **1512** as the air is displaced from the sequestration chamber **1508** by blood being forced into the sequestration chamber **1508** by a patient's own blood pressure. The protective cover **1516** can be constructed to inhibit or prevent accidental exposure of the filter to environmental fluids or splashes. This can be accomplished in a variety of mechanical ways including but not limited to the addition of a hydrophobic membrane to the protective cover.

(74) FIG. 15B is a perspective view of the blood sequestration device **1500** from the outlet port **1504** and top side of a housing **1501** of the blood sequestration device **1500** that includes the vent **1510**, and illustrating an initial aliquot of blood filling sequestration chamber **1508** while the sampling channel **1506** is empty, before a sample collection device is activated. FIG. 15G is a perspective view of the blood sequestration device **1500** from the outlet port **1504** and bottom side of the housing **1501** of the blood sequestration device **1500**, and illustrating the initial aliquot of blood filling sequestration chamber **1508** while the sampling channel **1506** is empty, before the sample collection device is activated. FIG. 15C is another perspective view of the blood sequestration device **1500** from the inlet port **1502** and top side of a housing **1501** of the blood sequestration device **1500** that includes the vent **1510**, and illustrating blood now being drawn through sampling channel **1506** while the sequestered blood remains substantially in the sequestration chamber **1508**.

(75) FIG. 15D is a cross section of the blood sequestration device **1500** in accordance with some implementations, showing the housing **1501** that defines the sampling channel **1506** and the sequestration chamber **1508**. FIGS. 15E and 15F illustrate various form factors of a housing for a blood sequestration device, in accordance with one or more implementations described herein.

(76) The sequestration chamber **1508** can have a larger cross-sectional area than the sampling channel **1506**, and the cross-sectional area and length can be configured for a predetermined or specific volume of blood to be sequestered or locked. The sampling channel **1506** can be sized to be compatible with tubing for either or both of the patient needle tubing or the blood collection device tubing.

(77) The housing **1501** can be formed of multiple parts or a single, unitary part. In some implementations, and as illustrated in FIG. 15D, the housing **1501** includes a top member **1520** and a bottom member **1522** that are mated together, one or both of which having grooves, channels, locks, conduits or other pathways pre-formed therein, such as by an injection molding process or

by etching, cutting, drilling, etc. The top member **1520** can be connected with the bottom member **1522** by any mating or connection mechanism, such as by laser welding, thermal bonding, ultrasonic welding, gluing, using screws, rivets, bolts, or the like, or by other mating mechanisms such as latches, grooves, tongues, pins, flanges, or the like.

(78) In some implementations, such as shown in FIG. **15D**, the top member **1520** can include the grooves, channels, locks, conduits or other pathways, while the bottom member **1522** can include a protrusion **1524** that is sized and adapted to fit into at least one of the grooves, channels, locks or other pathways of the top member **1520**. The protrusion **1524** can provide a surface feature, such as a partial groove or channel, for instance, to complete the formation of either the sampling channel **1506** and/or the sequestration chamber **1508**. In some implementations, the protrusion **1524** can be formed with one or more angled sides or surfaces for a tighter fit within the corresponding groove, channel, lock or other pathway. In yet other implementations, both the top member **1520** and the bottom member can include grooves, channels, locks or other pathways, as well as one or more protrusions **1524**.

(79) In some implementations, the sampling channel **1506** and the sequestration chamber **1508** are formed by grooves, channels, locks or other pathways formed in housing **1501**. The housing **1501** can be made of any suitable material, including rubber, plastic, metal or other material. The housing **1501** can be formed of a clear or translucent material, or of an opaque or non-translucent material. In other implementations, the housing **1501** can be mostly opaque or non-translucent, while the housing surface directly adjacent to the sampling channel **1506** and/or the sequestration chamber **1508** is clear or translucent, giving a practitioner a visual cue or sign that the sequestration chamber **1508** is first filled to the extent necessary or desired, and/or then a visual cue or sign that the sequestered blood remains sequestered while a clean sample of blood is drawn through the sampling channel **1506**. Other visual cues or signs of the sequestration can include, without limitation: the air permeable blood barrier **1512** turning a different color upon contact, saturation, or partial saturation with blood; a color-coded tab or indicator at any point along or adjacent to the sequestration chamber; an audible signal; a vibratory signal; or other signal.

(80) After a venipuncture by a patient needle of a patient (not shown), which could gather a number of pathogens from the patient's skin, a first amount of the patient's blood with those pathogens will make its way into the input port **1502** blood sequestration device **1500** and flow into the sequestration chamber **1508** by following the path of least resistance, as the patient's own blood pressure overcomes the atmospheric pressure in the sequestration chamber **1508** to displace air therein through the air permeable blood barrier **1512**. The patient's blood pressure will not be sufficient to overcome the air pressure that builds up in the sealed sampling channel **1506**. Eventually, the sequestration chamber **1508**, which has a predetermined volume, is filled with blood that displaces air through the air permeable blood barrier **1512**. Once the blood hits the air permeable blood barrier, the blood interacts with the air permeable blood barrier **1512** material to completely or partially seal the vent **1510**. A signal or indication may be provided that the practitioner can now utilize the Vacutainer capsule or other blood sample collection device to acquire a next amount of the patient's blood for sampling. The blood in the sequestration chamber **1508** is now effectively sequestered in the sequestration chamber.

(81) Upon filling the blood sequestration pathway **1508** but prior to use of the Vacutainer or other blood sample collection device, the patient's blood pressure may drive compression of the air in the sampling channel **1506**, possibly resulting in a small amount of blood moving past the diversion point to the sequestration chamber **1508** and into the sampling channel **1506**, queuing up the uncontaminated blood to be drawn through the sampling channel **1506**.

(82) FIGS. **16-19** illustrate yet another implementation of a blood sequestration device. FIGS. **16A-16D** illustrate a blood sequestration device **1600** that can be connected between a blood sample collection device, such as an evacuated blood collection container like a Vacutainer™ (not shown), and a patient needle (not shown) and/or associated tubing. FIG. **17** illustrates a bottom member of

the blood sequestration device, and FIG. 18 illustrates a top member of the blood sequestration device, which top member and bottom member can be mated together to form an input port, and output port, a sequestration chamber and a sampling channel, as explained more fully below. FIGS. 19A and B show the top member and bottom member mated together. It should be understood that FIGS. 16-19 illustrate one exemplary manner of constructing a blood sequestration device as described herein, and other forms of construction are possible.

(83) Referring to FIGS. 16A-D, the blood sequestration device **1600** includes an inlet port **1602** that can be connected with a patient needle that is inserted into a patient's vascular system for access to and withdrawing of a blood sample. The inlet port **1602** may also be connected with tubing or other conduit that is in turn connected with the patient needle. The inlet port **1602** defines an opening into the blood sequestration device **1600**, which opening can be the same cross sectional dimensions as tubing or other conduit connected with the patient needle or the patient needle itself. For instance, the opening can be circular with a diameter of approximately 0.045 inches, but can have a diameter of between 0.01 inches or less to 0.2 inches or more.

(84) The inlet port **1602** can also include a scaling or fluid-tight connector or connection, such as threading or Luer fitting, or the like. In some implementations, tubing or other conduit associated with the patient needle can be integral with the inlet port **1602**, such as by co-molding, gluing, laser weld, or thermally bonding the parts together. In this manner, the blood sequestration device **1600** can be fabricated and sold with the patient needle and/or tubing as a single unit, eliminating the need for connecting the patient needle to the blood sequestration device **1600** at the time of blood draw or sampling.

(85) The blood sequestration device **1600** further includes an outlet port **1604**, which defines an opening out of the blood sequestration device **1600** and to the blood sample collection device. The outlet port **1604** may also be connected with tubing or other conduit that is in turn connected with the blood sequestration device, and may also include a sealing or fluid-tight connector or connection, such as threading or Luer fitting, or the like. Accordingly, as discussed above, the blood sequestration device **1600** can be fabricated and sold with the patient needle and/or tubing and the blood sample collection device as a single unit, eliminating the need for connecting the patient needle and the blood sample collection device to the blood sequestration device **1600** at the time of blood draw or sampling.

(86) The blood sequestration device **1600** further includes a sampling channel **1606** between the inlet port **1602** and the outlet port **1604**, and a sequestration chamber **1608** that is connected to and split off or diverted from the sampling channel **1606** at any point between the inlet port **1602** and the outlet port **1604**. The sampling channel **1606** functions as a blood sampling pathway once a first aliquot of blood has been sequestered in the sequestration chamber **1608**. The sampling channel **1606** can be any sized, shaped or configured channel, or conduit. In some implementations, the sampling channel **1606** has a substantially similar cross sectional area as the opening of the inlet port **1602**. In other implementations, the sampling channel **1606** can gradually widen from the inlet port **1602** to the outlet port **1604**. The sequestration chamber **1608** may have a larger cross section to form a big reservoir toward the sequestration channel path so that the blood will want to enter the reservoir first versus entering a smaller diameter on the sampling channel **1606**, as is shown more fully in FIGS. 17 and 19.

(87) In some exemplary implementations, the diversion between the sampling channel **1606** and the sequestration chamber **1608** is by diverter junction **1607**. Diverter junction **1607** may be a substantially Y-shaped, T-shaped, or U-shaped. In some preferred exemplary implementations, and as shown in FIG. 17A-17B, the diverter junction **1607** is configured such that the flow out of the inlet port **1602** is preferentially directed toward the sequestration chamber **1608**. The sequestration chamber **1608** may also include or form a curve or ramp to direct the initial blood flow toward and into the sequestration chamber **1608**.

(88) The sequestration chamber **1608** is preferably maintained at atmospheric pressure, and

includes a vent **1610** at or near a distal end of the sequestration chamber **1608**. The vent **1610** may include an air permeable blood barrier **1612** as described above.

(89) The blood sequestration device **1600** can include a housing **1601** that can be formed of multiple parts or a single, unitary part. In some implementations, and as illustrated in FIGS. **17A-17E** and FIGS. **18A-18F**, the housing **1601** includes a top member **1620** and a bottom member **1622** that are mated together. The blood sequestration device **1600** can also include a gasket or other sealing member (not shown) so that when the top member **1620** is mechanically attached with the bottom member **1622**, the interface between the two is sealed by the gasket or sealing member. The FIGS. **17A-17E** illustrate a bottom member **1622** of a housing for a blood sequestration device **1600**. The bottom member **1622** can include grooves, channels, locks, conduits or other pathways pre-formed therein, such as by an injection molding process or by etching, cutting, drilling, etc., to form the sampling channel **1606**, the sequestration chamber **1608**, and diverter junction **1607**.

(90) The sequestration chamber **1608** may have a larger cross section than the sampling channel **1606** so that the blood will preferentially move into the sequestration chamber first versus entering a smaller diameter on the sampling channel **1606**.

(91) FIGS. **18A-18F** illustrate the top member **1620**, which can be connected with the bottom member **1622** by any mating or connection mechanism, such as by laser welding, thermal bonding, gluing, using screws, rivets, bolts, or the like, or by other mating mechanisms such as latches, grooves, tongues, pins, flanges, or the like. The top member **1620** can include some or all of the grooves, channels, locks, conduits or other pathways to form the sampling channel **1606**, the sequestration chamber **1608**, and the diverter junction **1607**. In yet other implementations, both the top member **1620** and the bottom member **1622** can include the grooves, channels, locks or other pathways.

(92) In some implementations, the sampling channel **1606** and the sequestration chamber **1608** are formed by grooves, channels, locks or other pathways formed in housing **1601**. The housing **1601** can be made of rubber, plastic, metal or any other suitable material. The housing **1601** can be formed of a clear or translucent material, or of an opaque or non-translucent material. In other implementations, the housing **1601** can be mostly opaque or non-translucent, while the housing surface directly adjacent to the sampling channel **1606** and/or the sequestration chamber **1608** may be clear or translucent, giving a practitioner a visual cue or sign that the sequestration chamber **1608** is first filled to the extent necessary or desired, and/or then a visual cue or sign that the sequestered blood remains sequestered while a clean sample of blood is drawn through the sampling channel **1606**. Other visual cues or signs of the sequestration can include, without limitation: the air permeable blood barrier **1612** turning a different color upon contact, saturation, or partial saturation with blood; a color-coded tab or indicator at any point along or adjacent to the sequestration chamber; an audible signal; a vibratory signal; or other signal.

(93) As shown in FIGS. **18A-18F**, the air permeable blood barrier **1612** can be covered with, or surrounded by, a protective member **1616**. The protective member **1616** can be sized and configured to inhibit a user from touching the air permeable blood barrier **1612** with their finger or other external implement, while still allowing air to exit the air permeable blood barrier **1612** as the air is displaced from the sequestration chamber **1608**. In some implementations, the protective member **1616** includes a protrusion that extends up from a top surface of the top member **1620** and around the air permeable blood barrier **1612**. The protective cover **1616** can be constructed to inhibit or prevent accidental exposure of the filter to environmental fluids or splashes. This can be accomplished in a variety of mechanical ways including but not limited to the addition of a hydrophobic membrane to the protective cover.

(94) In use, the blood sequestration device **1600** includes a sampling channel **1606** and a sequestration chamber **1608**. Both pathways are initially air-filled at atmospheric pressure, but the sampling channel **1606** is directed to an output port **1604** that will be initially sealed by a Vacutainer or other such sealed blood sampling device, and the sequestration chamber **1608**

terminates at a vent **1610** to atmosphere that includes an air permeable blood barrier **1612**.

(95) After a venipuncture by a patient needle of a patient (not shown), which could gather a number of pathogens from the patient's skin, a first amount of the patient's blood with those pathogens will pass through input port **1602** of blood sequestration device **1600**. This initial volume of potentially contaminated blood will preferentially flow into the sequestration chamber **1608** by finding the path of least resistance. The patient's own blood pressure overcomes the atmospheric pressure in the vented sequestration chamber **1608** to displace air therein through the air permeable blood barrier **1612**, but is not sufficient to overcome the air pressure that builds up in the sealed sampling channel **1606**. In various exemplary embodiments, the sequestration chamber **1608** and sampling channel **1606** can be configured such that the force generated by the patient's blood pressure is sufficient to overcome any effect of gravity, regardless of the blood sequestration device's orientation.

(96) Eventually, the sequestration chamber **1608** fills with blood that displaces air through the air permeable blood barrier **1612**. Once the blood contacts the air permeable blood barrier, the blood interacts with the air permeable blood barrier **1612** material to completely or partially seal the vent **1610**. A signal or indication may be provided that the practitioner can now utilize the Vacutainer or other blood sampling device.

(97) Upon filling the blood sequestration pathway **1608** but prior to use of the Vacutainer or other blood sample collection device, the patient's blood pressure may drive compression of the air in the sampling channel **1606**, possibly resulting in a small amount of blood moving past the diversion point into the sampling channel **1606**, queuing up the uncontaminated blood to be drawn through the sampling channel **1606**.

(98) FIG. **19A** is a side view, and FIG. **19B** is a cross-sectional view, of the blood sequestration device **1600**, illustrating the top member **1620** mated with the bottom member **1622**.

(99) FIG. **20** shows a blood sample optimization system **2000** that includes a patient needle **2002** for vascular access to a patient's bloodstream, a blood sample collection device **2004** to facilitate the collecting of one or more blood samples, and a conduit **2006** providing a fluid connection between the patient needle **2002** and the blood sample collection device **2004**. In some implementations, the blood sample collection device **2004** includes a protective shield that includes a sealed collection needle on which a sealed vacuum-loaded container is placed, which, once pierced by the collection needle, draws in a blood sample under vacuum pressure or force through the conduit **2006** from the patient needle **2002**.

(100) The blood sample optimization system **2000** further includes a blood sequestration device **2008**, located at any point on the conduit **2006** between the patient needle **2002** and the blood sample collection device **2004** as described herein.

(101) FIG. **21** illustrates a non-vented blood sequestration device **2100** using a wicking material chamber. The blood sequestration device **2100** includes a housing **2101** that has a sampling channel **2104** that is at least partially surrounded or abutted by a sequestration chamber **2102** that is filled with a wicking material. An initial aliquot of blood is drawn in from the patient needle into the sampling channel **2104** where it is immediately wicked into the wicking material of the sequestration chamber **2102**. The wicking material and/or sequestration chamber **2102** is sized and adapted to receive and hold a predetermined amount of blood, such that follow-on or later blood draws pass by the wicking material and flow straight through the sampling channel **2104** to a sampling device such as a Vacutainer. The wicking material can include a substance such as a solidifier, a decontaminate, or other additive.

(102) As described herein, an air permeable blood barrier may be created using a wide variety of different structures and materials. As shown in FIGS. **22A** and **B**, an air permeable blood barrier **2202** of a blood sequestration device **2200** can include a polymer bead matrix **2204**, in which at least some beads are treated to make them hydrophilic. The air permeable blood barrier **2202** further includes a self-scaling material **2206**, such as carboxymethyl cellulose (CMC) or cellulose

gum, or other sealing material. The air permeable blood barrier **2202** can further include voids **2208** that permit air flow before contact or during partial contact with a fluid such as blood. As shown in FIG. **22B**, contact with a fluid causes the self-sealing material **2206** to swell and close off the voids **2208**, occluding air flow through the voids **2208** and creating a complete or partial seal. (103) FIGS. **23A** and **B** illustrate yet another implementation of a blood sequestration device **2300**, having an inlet port **2302** to connect with a patient needle, an outlet port **2304** to connect with a blood sample collection device, a sequestration chamber **2306**, and a sampling channel **2308** that bypasses the sequestration chamber **2306** once the sequestration chamber is filled to an initial aliquot of potentially contaminated blood to be sequestered. The sequestration chamber **2306** includes a hydrophobic plug **2312** at a distal end of the sequestration chamber **2306** that is farthest from the inlet port **2302**. A vacuum or other drawing force applied from the outlet port **2304**, such as from a Vacutainer or the like, draws in blood into the inlet port **2302** and directly into the sequestration chamber **2306**, where the initial aliquot of blood will contact the hydrophobic plug **2312** and cause the initial aliquot of blood to back up into the sequestration chamber **2306** and be sequestered there. A small amount of blood may make its way into the sampling channel **2308**, which is initially closed off by valve **2308**. Upon release of the valve **2308**, and under further force of the vacuum or other force, follow-on amounts of blood will flow into inlet port **2302**, bypass the sequestration chamber **2306**, and flow into and through sampling channel **2308** toward the outlet port **2304** and to the collection device.

(104) The sampling channel **2308** can have any suitable geometry and can be formed of plastic tubing or any other suitable material. Valve **2308** can be a clip or other enclosing device to pinch, shunt, bend or otherwise close off the sampling channel before the initial aliquot of blood is sequestered in the sequestration chamber **2306**.

(105) Although a variety of embodiments have been described in detail above, other modifications are possible. Other embodiments may be within the scope of the following claims.

## Claims

1. A device comprising: an inlet port for receiving a blood sample; an outlet port; a chamber connected with the inlet port and configured to collect a first portion of the blood sample when under a drawing force applied from the outlet port from a blood sample collection device; and a sampling channel connected with the inlet port and configured to convey a subsequent portion of the blood sample to the outlet port.
2. The device in accordance with claim 1, wherein a blood impermeable membrane is configured to facilitate the chamber collecting the first portion of the blood sample.
3. The device in accordance with claim 1, wherein a blood impermeable membrane causes the first portion of the blood sample to back up into the chamber following application of the drawing force applied from the outlet port.
4. The device in accordance with claim 2, further comprising a housing, separate from the blood impermeable membrane.
5. The device in accordance with claim 1, wherein the device is configured such that, when the drawing force is applied at the outlet port, the first portion of the blood sample is drawn into the chamber to contact a material that is blood impermeable.
6. The device in accordance with claim 1, further comprising a valve configured to initially close off the sampling channel.
7. The device in accordance with claim 1, further comprising a valve configured to initially close off the sampling channel until the first portion of the blood sample is in the chamber.
8. The device in accordance with claim 1, further comprising a valve that is configured to initially close off the sampling channel until the first portion of the blood sample is in the chamber and is further configured such that, upon release, follow-on amounts of the blood sample will bypass the

chamber and flow through the sampling channel toward the outlet port.

9. The device in accordance with claim 6, wherein the valve is configured to pinch, shunt, bend or otherwise close off the sampling channel before the first portion of the blood sample is collected in the chamber.

10. The device in accordance with claim 1, further comprising a patient needle and the blood sample collection device.

11. The device in accordance with claim 1, the chamber having a volume sufficient to collect the first portion of the blood sample that is more prone to contamination and also to minimize an amount of blood to be sequestered.

12. The device in accordance with claim 1, wherein the chamber has a volume of less than 1.5 cubic centimeters.

13. A device comprising: an inlet port for receiving blood; an outlet port; a chamber comprising a flexible material, the chamber connected with the inlet port and configured to collect a first portion of the blood when under a drawing force applied from the outlet port; and a sampling channel connected with the inlet port and configured to convey a subsequent portion of the blood to the outlet port.

14. The device in accordance with claim 13, wherein the flexible material is a blood impermeable membrane configured to facilitate the chamber collecting the first portion of the blood.

15. The device in accordance with claim 13, wherein the flexible material is a blood impermeable membrane causes the first portion of the blood to back up into the chamber following application of the drawing force applied from the outlet port.

16. The device in accordance with claim 14, further comprising a housing, separate from the blood impermeable membrane.

17. The device in accordance with claim 13, wherein the device is configured such that, when the drawing force is applied at the outlet port, the first portion of the blood is drawn into the chamber to contact a material that is blood impermeable.

18. The device in accordance with claim 13, further comprising a valve configured to initially close off the sampling channel.

19. The device in accordance with claim 13, further comprising a valve configured to initially close off the sampling channel until the first portion of the blood is in the chamber.

20. The device in accordance with claim 13, further comprising a valve that is configured to initially close off the sampling channel until the first portion of the blood is in the chamber and is further configured such that, upon release, follow-on amounts of the blood will bypass the chamber and flow through the sampling channel toward the outlet port.

21. The device in accordance with claim 18, wherein the valve is configured to pinch, shunt, bend or otherwise close off the sampling channel before the first portion of the blood is collected in the chamber.

22. The device in accordance with claim 13, further comprising a patient needle and a sample collection device.

23. The device in accordance with claim 13, the chamber having a volume sufficient to collect the first portion of the blood that is more prone to contamination and also to minimize an amount of blood to be sequestered.

24. The device in accordance with claim 13, wherein the chamber has a volume of less than 1.5 cubic centimeters.

---